Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial

NCT03671967 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.

NCT NCT03671967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03671967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial
Lead sponsor
Rambam Health Care Campus
Phase
Phase 4
Overall status
Recruiting
Start date
May 1, 2019
Completion date
April 1, 2027
Enrollment
1,084 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

bacteremia, beta lactam resistant bacterial infection, enterobacteriaceae infections